Wells Fargo & Company Landos Biopharma, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.26 - $0.55 $0 - $1	2 Added 1.87%	109 $0
Q4 2022 Feb 13, 2023	BUY	$0.22 - $0.51 $0 - $1	3 Added 2.88%	107 $0
Q3 2022 Nov 14, 2022	SELL	$0.67 - $1.26 $2,639 - $4,963	-3,939 Reduced 97.43%	104 $0
Q2 2022 Aug 12, 2022	BUY	$0.6 - $1.5 $2,305 - $5,764	3,843 Added 1921.5%	4,043 $3,000
Q1 2022 May 16, 2022	BUY	$1.44 - $5.22 $267 - $970	186 Added 1328.57%	200 $0
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $65 - $210	14 New	14 $0
Q3 2021 Nov 15, 2021	SELL	$9.77 - $15.77 $93,069 - $150,225	-9,526 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.26 - $12.53 $69,931 - $94,626	7,552 Added 382.57%	9,526 $110,000
Q1 2021 May 13, 2021	BUY	$9.47 - $16.26 $18,693 - $32,097	1,974 New	1,974 $19,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.